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Development of new anticancer drugs has resulted in improved mor-
tality rates and 5-year survival rates in patients with cancer. However,
many of the modern chemotherapies are associated with cardiovas-
cular toxicities that increase cardiovascular risk in cancer patients,
including hypertension, thrombosis, heart failure, cardiomyopathy, and
arrhythmias. These limitations restrict treatment options and might
negatively affect the management of cancer. The cardiotoxic effects of
older chemotherapeutic drugs such as alkylating agents, antimetabo-
lites, and anticancer antibiotics have been known for a while. The
newer agents, such as the antiangiogenic drugs that inhibit vascular
endothelial growth factor signalling are also associated with cardio-
vascular pathology, especially hypertension, thromboembolism,
myocardial infarction, and proteinuria. Exact mechanisms by which
vascular endothelial growth factor inhibitors cause these complica-
tions are unclear but impaired endothelial function, vascular and renal
damage, oxidative stress, and thrombosis might be important. With
increasing use of modern chemotherapies and prolonged survival of
cancer patients, the incidence of cardiovascular disease in this patient
population will continue to increase. Accordingly, careful assessmentReceived for publication November 19, 2015. Accepted December 21, 2015.
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La mise au point de nouveaux medicaments anticancereux a permis
de reduire le taux de mortalite et d’ameliorer le taux de survie après 5
ans des patients atteints de cancer. Cependant, nombre de ces nou-
veaux anticancereux sont associes à une toxicite cardiovasculaire qui
accroît le risque cardiovasculaire de ces patients, notamment en ce
qui a trait à l’hypertension, à la thrombose, à l’insuffisance cardiaque,
à la cardiomyopathie et à l’arythmie. Cette problematique limite les
choix de traitement et peut avoir une incidence negative sur la prise en
charge du cancer. La cardiotoxicite des anticancereux plus anciens
comme les agents alkylants, les antimetabolites et les antibiotiques
anticancereux est connue depuis assez longtemps. Les nouveaux
agents comme les antiangiogeniques, qui inhibent l’expression de
facteurs de croissance endotheliale vasculaire, sont egalement
associes à des pathologies cardiovasculaires, plus particulièrement à
l’hypertension, à la thromboembolie, à l’infarctus du myocarde et à la
proteinurie. Le mecanisme causal exact des complications liees aux
antiangiogeniques demeure encore inexplique, mais la dysfonction
endotheliale, les dommages vasculaires et renaux, le stress oxydatif et
la thrombose pourraient être des facteurs importants. Le recours deAdvancements in the treatment of cancer have improved the
prognosis of patients with a wide range of malignancies,1 to
the extent that treatment is now often given with curative
intent.2 In tandem with the improved survival from cancer,
there has been increasing focus on cardiovascular actions of
chemotherapeutic agents. In addition to acute toxic vascular
effects of chemotherapeutic agents, the latent effects of direct
and indirect cardiovascular toxicity become more relevant.
Patients now frequently survive long enough to allow these
effects to manifest and become the prime concern.3 It has
become increasingly complex to establish a pragmatic balancebetween effective anticancer therapy while mitigating the risks
of cardiovascular complications. As a result, cardio-oncology is
rapidly growing as a cardiovascular subspecialty in its own
right.
Heart failure and heart muscle toxicity induced by
chemotherapy, particularly anthracyclines and HER2 receptor
antagonists, have benefited from an expanding recognition
and evidence base to inform strategies to mitigate the risk of
this potentially devastating complication. However, in
contrast, there is a smaller evidence base and mechanistic
insight to the vascular complications associated with cancer
chemotherapeutics. Many conventional chemotherapy agents,
as well as some of the newer anticancer signalling inhibitors
and antiangiogenic drugs, predispose patients to cardiovas-
cular side effects including hypertension, acute coronary
syndromes, and arterial and venous thrombosis (Table 1).1,2
Vascular complications of chemotherapy might occur as a
result of ‘off-target’ drug effects or, importantly, as a result of
the significant overlap between signalling pathways required
for normal vascular function and those required for tumourn Cardiovascular Society. This is an open access article under the CC BY-NC-
and management of cardiovascular risk factors in cancer patients by
oncologists and cardiologists working together is essential for optimal
care so that prolonged cancer survival is not at the expense of
increased cardiovascular events.
plus en plus frequent aux nouvelles chimiotherapies et la prolongation
de la survie des patients feront encore augmenter l’incidence des
maladies cardiovasculaires dans cette population. Les oncologues
devront donc travailler de pair avec les cardiologues afin de
soigneusement evaluer et prendre en charge les facteurs de risque
cardiovasculaire pour assurer les meilleurs soins possibles et ainsi
eviter que la prolongation de la survie des patients se fasse au prix
d’un nombre accru d’evenements cardiovasculaires.
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Cancer Drugs and Vascular Complicationsgrowth. Vascular toxicity of chemotherapy often reflects
endothelial dysfunction, with loss of vasorelaxant effects and
suppressed anti-inflammatory and vascular reparative func-
tions. These effects might serve to initiate and further
perpetuate the development of hypertension, thrombosis, and
atherogenesis. In addition to the procoagulant effect of cancer
per se, platelet activity is further enhanced by decreased
endothelial nitric oxide (NO) bioavailability.2
The propensity to develop cardiovascular complications of
cancer therapy reflects the complex interplay between a
patient’s baseline cardiovascular risk and preexisting vascular
disease, particularly hypertension and diabetes, whilst
evidence for genetic predisposition is increasing (Fig. 1).4
Optimal strategies for the diagnosis, surveillance, and
management of cardiovascular complications in patients who
receive chemotherapy agents remain incompletely defined and
can be challenging.1 Baseline cardiovascular assessment is vital
before the selection of appropriate chemotherapy and preex-
isting cardiovascular disease must be treated aggressively
(Fig. 2). Baseline endothelial function is a risk marker for the
development of cardiovascular events and correlates well with
traditional cardiovascular risk factors in the ‘noncancer’ pop-
ulation. Assessment of endothelial function could therefore beTable 1. Chemotherapy agents with principal cardiovascular complications
Chemotherapy drug class Chemotherapy agents Princip
VEGF signalling pathway inhibitors
Bevacizumab
Sunitinib
Sorafenib
Hypertensio
Ischemia
Thromboem
Tyrosine kinase inhibitors for hematological malignancy
Ponatinib
Nilotinib
Dasatinib
Ischemia
Alkylating agents
Cisplatin Hypertensio
Ischemia
Thromboem
Nephrotoxic
Antimetabolites
5-Fluorouracil Ischemia
Anthracyclines
Doxorubicin
Epirubicin
Cardiotoxici
Approximate frequency of complications indicated by þ (< 5%), þþ (5%-10%
ET, endothelin; PGI2, prostacyclin; NO, nitric oxide; VEGF, vascular endothela useful tool for identification of asymptomatic subjects at
high cardiovascular risk, and stratification of risk among
subjects with known cardiovascular disease before consider-
ation of chemotherapy.5 This strategy is not, however,
currently used in routine clinical practice.
It might be appropriate to avoid some chemotherapy
agents in patients at high risk of vascular complications and in
others the potential for vascular toxicity might be safely
managed without affecting the net benefit from chemo-
therapy.2 Careful stratification of such patients might lead to
reduced cardiovascular morbidity in cancer patients who
receive chemotherapy. Indeed, distilling the relative likelihood
of vascular toxicity against the anticancer effects of chemo-
therapy remains an enormous challenge and highlights the
absolute requirement for close collaboration between oncol-
ogists and cardiovascular specialists. Ongoing and targeted
vascular evaluation during treatment is important, often with
the early introduction of secondary preventive treatments that
might need to be used in a context outwith the evidence base
derived from major cardiovascular trials. There remains an
unmet need to better stratify patients who might require
much longer follow-up or preventative vascular therapies,
potentially for years after cancer treatments have ended.and potential mechanisms
le cardiovascular complications Potential mechanisms
n þþþþ Endothelial dysfunction
Y NO signalling
[ ET signalling
Capillary rarefaction
Vascular remodelling
Oxidative stress
bolism
þ Platelet activation
Y NO and PGI2 signalling
þþþþ Acute arterial thrombosis
n þþþþ Endothelial dysfunction
bolism
þþ Platelet activation
Y NO and PGI2 signalling
Vasospasm
ity þþþþ Endothelial dysfunction
þþþþ Vasospasm
ty þþþ Myocyte apoptosis
), þþþ (10%-20%), and þþþþ (> 20%).
ial growth factor.
Figure 1. Diagram illustrating factors that possibly contribute to chemotherapy-associated vascular toxicity. Multiple stimuli, such as cardiovas-
cular risk factors, cancer itself, and anticancer drugs, influence vascular function and arterial structure leading to increased reactivity, altered
vascular tone, impaired endothelial function, and platelet activation. These processes in turn contribute to cardiovascular disease, such as hy-
pertension, cardiac ischemia and thrombosis, which might be facilitated and aggravated by chemotherapy in cancer patients. ET-1, endothelin-1;
NO, nitric oxide; PGI2, prostacyclin.
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Volume 32 2016In this review we provide a clinically relevant overview of
vascular toxicity associated with major classes of chemotherapy
drugs. Although a large body of work addresses significant
problems associated with drug-induced heart muscle toxicity
and heart failure,1,4 we focus on the vascular effects, partic-
ularly hypertension, and arterial and venous thrombosis.Vascular Endothelial Growth Factor Inhibitors
Angiogenesis, the process of new blood vessel formation, is
central to solid tumour growth and metastasis,6,7 and is
therefore an ideal target for anticancer therapy. Vascular
endothelial growth factor (VEGF) is among the most
important of growth factors involved in angiogenesis. VEGF is
a 45-kDa glycoprotein produced by many cell types, including
endothelial progenitor cells, endothelial cells, renal epithelial
cells, fibroblasts, macrophages, and certain tumours.8 The
VEGF gene undergoes alternative splicing to form multiple
isoforms: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and
placental growth factor. VEGF-A, the best characterized,
binds to 3 types of tyrosine kinase receptors (VEGF receptor
[VEGFR]1, VEGFR2, and VEGFR3).8,9 VEGFR1 and
VEGFR2 are expressed predominantly in endothelial cells,
with VEGF-A binding to VEGFR2 having the major vascular
effects. Activation of VEGFR2 by ligand binding initiates
signalling through tyrosine kinases that stimulate many
pathways, including phosphoinositide 3-kinase/AKT/protein
kinase B-mammalian target of rapamycin, endothelial NOsynthase, and prostacyclin, that regulate vasodilation and
inflammatory responses.10,11 VEGF also signals through
phospholipase C, Raf-1, and mitogen-activated protein
kinases, pathways that regulate endothelial cell survival,
proliferation, migration, and permeability.12
Chemotherapy agents might influence VEGF effects
directly, as is the case for VEGF inhibitors (VEGFIs), or as a
secondary effect as occurs with the ‘classical’ cytotoxic drugs,
including antimetabolites, taxanes, anthracyclines, and alky-
lating agents.5,13,14 Interruption of VEGF signalling is asso-
ciated with the development of vascular toxicity and clinical
sequelae such as hypertension, acute coronary syndromes,
stroke, venous thrombosis, and thromboembolism.5,15-18
VEGFIs are now the cornerstone of therapy for a wide
variety of solid tumours and hematological malignancies.
There are 3 main groups of VEGFIs: (1) monoclonal anti-
bodies against circulating VEGF (eg, bevacizumab [Avastin;
Roche]). This class of agent selectively binds to circulating
VEGF to inhibit its interaction with the VEGFR. As such, it
is considered a relatively specific VEGF signalling pathway
antagonist; (2) small-molecule inhibitors of intracellular
tyrosine kinases (eg, sunitinib [Sutent; Pfizer]), sorafenib
[Nexavar; Bayer]). These agents are not VEGFR2-specific and
also inhibit other receptor tyrosine kinases, including platelet-
derived growth factor and c-Kit signalling, which are
implicated in tumour angiogenesis.19 This combined effect
increases antiangiogenic and anticancer efficacy but also
contributes to a greater risk of adverse cardiovascular
Figure 2. Clinical approach in assessing and managing hypertension
in cancer. Flow chart showing clinical approaches to the cardiovas-
cular assessment of patients before and during chemotherapy, and
the management of chemotherapy-associated hypertension. ACE,
angiotensin-converting enzyme; BP, blood pressure.
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Cancer Drugs and Vascular Complicationseffects19-23; and (3) VEGF ‘trap’ (eg, aflibercept [Zaltrap;
Sanofi]); this recombinant fusion protein comprises VEGF-
binding regions of VEGFRs 1 and 2.2,24
Hypertension
Hypertension is the most common cardiovascular
complication associated with VEGFIs.7 Almost all patients
have an absolute increase in blood pressure with most clinical
trials reporting increased blood pressure as an adverse effect
and up to 80% of patients developing hypertension that is
often severe and difficult to treat.7,25-27 The true prevalence of
VEGFI-induced hypertension might be underestimated
because of varying definitions used in clinical trials with blood
pressure thresholds often greater than those used in most
evidence-based guidelines.7,28 Furthermore, patients with
difficult to treat hypertension or a history of cardiovascular
disease are usually excluded from clinical trials.7 There have
been recent efforts to aid consistency in the diagnosis and
reporting of VEGFI-associated hypertension, which should
follow the 2014 Joint National Commission recommenda-
tions, with a threshold of 140/90 mm Hg on 3 occasions at
least 1 week apart in individuals aged younger than 60 years
and 150/90 mm Hg in those aged older than 60 years.7,29,30
The exact mechanisms of VEGFI-induced hypertension
are not fully understood but are believed to include endo-
thelial dysfunction, reduced NO generation andvasodilatation, increased endothelin-1 and vasoconstriction,
capillary rarefaction, vascular remodelling, and oxidative
stress.7,31-36 Recent data from animal models and early clinical
studies have suggested autonomic nervous system toxicity
might also contribute to VEGFI-associated hypertension.37
An acute, dose-dependent increase in blood pressure occurs
within hours to days of starting treatment and resolves rapidly
upon withdrawal of the agent.7,38 Patients with a history of
hypertension and those treated with multiple VEGFIs are at
particularly high risk.7,32-35,39
All patients should undergo a comprehensive assessment
screening for existing cardiovascular disease before treatment
with a VEGFI. This should include a history, physical
examination, and screening for end-organ damage (Fig. 2).
Thereafter, there should be active monitoring of blood pres-
sure during treatment, particularly in the first cycle when
blood pressure should be checked weekly, followed by every
2-3 weeks. Increased blood pressure should be treated
aggressively, aiming for a target of < 140/90 mm Hg.7,29,40,41
Angiotensin-converting enzyme inhibitors and dihydropyr-
idine calcium channel antagonists appear most effective in the
treatment of VEGFI-induced hypertension (Table 2),
although the evidence from which to draw these conclusions
remains relatively small. Thiazide diuretics, mineralocorticoid
receptor antagonists and b-blockers may be used if additional
antihypertensive agents are required.40,42,43 Angiotensin-
converting enzyme inhibitors also have the potential to
protect against proteinuria and direct cardiac toxicity associ-
ated with chemotherapy. Mineralocorticoid receptor antago-
nists are increasingly being used to treat resistant
hypertension43 and might therefore have a role in the man-
agement of VEGFI-associated hypertension.
Nondihydropyridine calcium channel antagonists, such as
verapamil or diltiazem, should be avoided because these agents
inhibit cytochrome P450 3A4, through which VEGFIs are
metabolized. The coprescription of verapamil or diltiazem can
provoke increased plasma antiangiogenic drug concentra-
tions.7 Care should also be taken to note potential ‘off periods’
in VEGFI regimens to avoid symptomatic rebound
hypotension.7
The use of NO donors or endothelin receptor antagonists
in the treatment of VEGFI-associated hypertension has yet to
be formally assessed in a rigourous trial. However, this
iatrogenic cause of hypertension might provide a ‘niche’ role
for endothelin receptor antagonists and preclinical data and
mechanistic insight provide enthusiasm for this approach.7
Thrombosis
Although VEGFIs have been associated with thrombotic
and hemorrhagic side effects,44,45 the prothrombotic effects
appear to predominate. VEGFIs are associated with an abso-
lute increase in risk of arterial and venous thrombosis and
thromboembolism of 1.5%-4%. The risk of arterial throm-
bosis appears to be greater than that of venous
thrombosis.4,46-48
Bevacizumab is associated with a 2.1-fold increased risk of
high-grade cardiac ischemia49; sorafenib was associated with a
3% incidence of myocardial ischemia or infarction,50 and a
study of sunitinib in patients with advanced clear-cell renal
carcinoma showed a 1% incidence of myocardial infarction
(MI).20
Table 2. Summary of the approaches to management of chemotherapy associated hypertension
Aspect of therapy Drug class Examples Indications/benefits Cautions/contraindications
First- and second-line
therapy
ACE inhibitors Captopril
Enalapril
Lisinopril
Perindopril
Ramipril
 VEGFI associated hypertension
 Younger patients
 Proteinuria
 Diabetic nephropathy
 Left ventricular dysfunction
 Quick onset of action
 Renovascular disease
 Peripheral vascular disease
 Renal impairment
 Chemotherapy with renal
clearance
 Hyperkalaemia
Angiotensin II receptor
antagonists
Candesartan
Irbesartan
Losartan
Valsartan
 VEGFI-associated hypertension
 Cough related to ACE inhibitor
 Younger patients
 Proteinuria
 Diabetic nephropathy
 Left ventricular dysfunction
 Quick onset of action
 Renovascular disease
 Peripheral vascular disease
 Renal impairment
 Chemotherapy with renal
clearance
 Hyperkalemia
Dihydropyridine calcium
channel antagonists
Amlodipine
Lercanidipine
 Cisplatin-associated hypertension
 Elderly patients
 Isolated systolic hypertension
 Ankle swelling
 Slow onset of action
Third-and fourth-line
therapy
Thiazide diuretics Bendroflumethiazide
Chlorthalidone
Hydrochlorothiazide
Indapamide
 Elderly patients
 Isolated systolic hypertension
 Gout
 Hypercalcaemia
 Hypokalaemia
 QTc prolonging drugs
Mineralocorticoid receptor
antagonists
Eplerenone
Spironolactone
 Resistant hypertension  Hyperkalemia
 Gynecomastia (spironolactone)
b-blockers Bisoprolol
Carvedilol
Metoprolol
 Ischemic heart disease  Bradycardia
 Heart block
 Asthma or COPD
Agents to avoid Non-dihydropyridine calcium
channel antagonists
Verapamil
Diltiazem
N/A
BP management during
chemotherapy “off periods”
or after stopping or
completing chemotherapy
 Monitor for rebound hypotension with or without downtitration or stop antihypertensive therapy
 Regular monitoring of blood pressure after stopping or completing chemotherapy
ACE, angiotensin-converting enzyme; BP, blood pressure; COPD, chronic obstructive pulmonary disease; N/A, not applicable; VEGFI, vascular endothelial
growth factor inhibitor.
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Volume 32 2016Faruque and colleagues showed a 3.5-fold increased risk of
MI and 1.8-fold increased risk of arterial thrombosis associ-
ated with VEGFI therapy.51 However, the absolute increase in
risk is relatively small (0.8% and 1.8% increased risk for MI
and arterial thrombosis, respectively), but clinically important,
particularly for those with preexisting risk factors or vascular
disease. Patients with previous coronary artery disease are at
particularly high risk of developing vascular complications4,52
and it might be reasonable to consider screening patients for
preexisting coronary artery disease before commencing anti-
angiogenic treatment, although the most appropriate method
remains unclear.4 Because the pathophysiologic mechanism
partly reflects increased platelet activation, as a consequence of
endothelial dysfunction, there might be a role for antiplatelet
therapy but concerns over coexisting propensity to hemor-
rhage have limited the applicability of this strategy. Insuffi-
cient data are available to clearly guide the optimum
preventative therapy,4 and the potential cardioprotective
effects of statin therapy in this context also remains to be
evaluated.4Tyrosine Kinase Inhibitors for Hematologic
Malignancy
Tyrosine kinase inhibitors (TKIs) developed for use in the
treatment of hematologic malignancy, including ponatinib,
nilotinib, and dasatinib, are associated with a particularly high
incidence of acute arterial thrombosis. This is particularly
evident for ponatinib,4 which acts as a potent multitargetedTKI against the oncogenic fusion gene, Bcr-Abl, and is used in
the treatment of chronic myeloid leukemia (CML) and
Philadelphia chromosome-positive acute lymphoblastic
leukemia resistant to, or intolerant of, traditional TKIs.4 Its
efficacy was shown in the Ponatinib for CML Evaluation and
Philadelphia Chromosome-Positive Acute Lymphoblastic
Leukemia trial, in which it had significant antileukemic action
across both groups of patients and categories of disease stage.53
It was, however, associated with an almost 12% incidence of
arterial thrombotic events at 2 years, with most events
occurring as an acute thrombotic process.4
Ponatinib is also associated with relatively high rates of
venous thrombosis, with an incidence of 2.2% at 1 year and
2.9% at 2 years. Although this association is clinically rele-
vant, the incidence of venous thrombosis is markedly lower
than that of arterial thrombosis. The high rates of vascular
events initially led to the withdrawal of ponatinib, although it
was reintroduced in 2014 with a US Food and Drug
Administration ‘black box’ warning.4
Nilotinib, also an anti-Bcr-Abl TKI, preceded the use of
ponatinib in the treatment of CML.4 It is also associated with
high rates of arterial thrombosis, with 25% of patients expe-
riencing an acute arterial event in the initial study.4,54 The 2-
year incidence of acute arterial event is almost 15% with a
33% predicted 10-year risk of progressive peripheral arterial
disease.4,55 The risk appears to remain high regardless of
baseline cardiovascular status.4,56 Furthermore, there appears
to be a predilection for peripheral arterial disease involving the
lower limbs, as well as the renal and mesenteric arteries, and
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pertension and ischemic nephropathy.4,57,58
Mechanisms underpinning the high incidence of acute
arterial events associated with ponatinib and nilotinib remain
unclear, although not all anti-Bcr-Abl TKIs are associated
with such high risk. The 10-year projected risk of developing
progressive peripheral arterial disease is 14 times greater with
nilotinib than with the prototype anti-Bcr-Abl TKI, imati-
nib.55 The reason for such a discrepancy remains unclear and
is not accounted for by age, sex, or traditional cardiovascular
risk factors.55 There might be as yet unidentified off-target
effects, as has been observed with TKIs of the VEGF signal-
ling pathway. Because the pathophysiological mechanisms
that contribute to the high risk of arterial vascular events
remain unclear, the most appropriate approaches to manage-
ment also remain unclear.4Alkylating Agents
Platinum-based compounds
Cisplatin is associated with acute and late cardiovascular
side effects, including hypertension, myocardial ischemia and
infarction, thromboembolism, and cerebrovascular disease.2,59
These effects might contribute to a cardiovascular risk profile
more concerning than the risk of cancer relapse or the
development of a second malignancy.5,60
Hypertension. Hypertension is a frequently reported
complication of cisplatin-based chemotherapy.5,60-64 The
prevalence varies with Sagstuen and colleagues reporting that
53% of patients treated with higher dose cisplatin therapy
developed hypertension over a median follow-up of 11 years
(odds ratio, 2.3; 95% confidence interval, 1.5 to-3.7, compared
with control participants).62 Other studies reported a preva-
lence that ranged from 39% of patients at least 10 years after
treatment,59 to 28% over 7 years,65 and 14% over 14 years.64
Strumberg and colleagues reported no significant increase in
systolic blood pressure after 13 years of follow-up after cisplatin-
based chemotherapy for testicular cancer, although 25% of
subjects developed diastolic hypertension.60 Overall, most
studies showed that a significant proportion of patients develop
persistent hypertension after cisplatin-based chemotherapy,
with endothelial cell activation, damage, and subsequent
endothelial dysfunction believed to be the main contributing
factor.5,61,64,66 Microalbuminuria, a marker of endothelial
dysfunction, occurs in up to 22% of patients at least 10 years
after cisplatin-based chemotherapy for metastatic testicular
cancer.59 Calcium channel antagonists appear most effective in
the treatment of hypertension associated with alkylating agents
such as cisplatin and patients treated with alkylating agents
should have long-term monitoring of their cardiovascular risk
profile, including blood pressure.
Thrombosis. Cisplatin-based chemotherapy is associated with
a 9% risk of thromboembolic complications.5,66,67 Potential
mechanisms that might contribute to thrombus formation
include endothelial cell damage and dysfunction provoking a
hypercoagulable state with platelet activation, adhesion, and
aggregation, increased vonWillebrand factor, and reduced NObioavailability.2,18,68 Cerebrovascular complications might
occur through thrombosis in situ as a consequence of endo-
thelial dysfunction or by thromboembolism.5 Furthermore,
cisplatin-associated hypertension might result in acute cardio-
vascular complications during therapy as well as contribute to
the initiation and progression of atherosclerotic cardiovascular
complications in the longer-term.5
Over a median follow-up of 14 years, cisplatin-based
chemotherapy for metastatic testicular cancer has been asso-
ciated with a sevenfold increased risk of major cardiac event
(6% of patients).59 Preclinical and clinical data provide
convincing evidence that the toxicity reflects primarily the
platinum (cisplatin) component of this regimen.59,69 Patients
previously treated with platinum-containing compounds also
show persistent adverse cardiovascular risk profiles, including
hypertension and hyperlipidemia.59,70 Fung and colleagues
recently showed an almost fivefold increased risk of cardio-
vascular mortality in the first year after testicular cancer
diagnosis in patients treated with cisplatin compared with
surgery alone.71 The risk of thrombotic complications
decreased markedly after 1 year. This large study should focus
our attention on the short- to medium-term effects of
platinum-based chemotherapy and suggests that the acute
toxic effects of platinum-based chemotherapy predominate
over concerns about an adverse cardiovascular risk profile in
the longer-term.
Although endothelial toxic effects of cisplatin-based
chemotherapy appear to be central in the pathophysiology
of associated complications, abnormalities in endothelial
function assessed using measures of brachial artery
flow-mediated dilatation have not shown a consistent effect
over time. When assessed within 10 weeks of administration
of platinum-based chemotherapy,69 no change in flow-
mediated dilatation was observed although marked decreases
were seen immediately after treatment72 and also at 1 year.73
Therefore, the time course of endothelial impairment remains
incompletely defined. It is conceivable that there is a biphasic
response with ‘hyperacute’ and partially reversible endothelial
toxicity in the immediate peritreatment period followed by a
subsequent decline as a result of a persistent adverse cardio-
vascular risk profile.
Cisplatin also has the potential to provoke vasospasm,
which might result in symptoms of angina, acute coronary
syndrome, and stroke.18 Additionally, cisplatin can provoke
hypomagnesemia, which might contribute to arrhythmias,
and alterations in vascular tone with coronary and cerebral
artery vasospasm.18,74Nephrotoxicity. Nephrotoxicity is a well documented
adverse effect of cisplatin use, with a dose-dependent and
irreversible reduction in renal function.75-77 Possible mecha-
nisms include endothelial and epithelial cell damage and
dysfunction.78 Patients treated with cisplatin-based chemo-
therapy have a high prevalence of microalbuminuria62,66 and
there are indications to suggest that patients who develop
microalbuminuria in association with cisplatin-based chemo-
therapy have higher blood pressure levels than those who do
not.59,62 This supports the hypothesis that endothelial
dysfunction and associated nephrotoxicity might contribute to
hypertension associated with cisplatin-based chemotherapy.62
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This alkylating agent is associated with vascular complica-
tions including hypertension, MI, stroke, Raynaud phenome-
non, and hepatic veno-occlusion. Circulating concentrations of
VEGF are reduced by cyclophosphamide administered at
continuous low doses, which might underpin some of the
observed vascular toxicity, as seen in patients treated with
VEGFIs. Notably, cyclophosphamide is also associated with the
development of interstitial pneumonia and pulmonary fibrosis,
with lung biopsy showing vascular sclerosis and signs of pul-
monary hypertension.5 This might be a consequence of reduced
angiotensin-converting enzyme activity as well as neutrophil
and monocyte adhesion to damaged endothelium with platelet
accumulation in endothelial lesions.5Antimetabolites: 5-Fluorouracil
5-Fluorouracil (5-FU) and its prodrug, capecitabine, are
mainly associated with myocardial ischemia, which might be
due to primary coronary artery spasm, thrombosis, or endo-
thelial dysfunction.1,2,18,79,80 Myocardial ischemia might
present as a broad spectrum from asymptomatic ST segment
changes on electrocardiogram through to angina, MI, and
sudden cardiac death.1 Most events occur early and the risk is
greatest when administered at high, repeated doses and as a
continuous infusion. Although endothelial cell damage and
thrombus formation might contribute to myocardial ischemia,
coronary artery vasospasm is believed to be the main patho-
genic factor.18,81,82 5-FU can exert direct toxic effects on
vascular endothelium to reduce endothelial NO synthase
activity and provoke coronary artery vasospasm, and
endothelium-independent vasoconstriction via protein kinase
C.5,83 The coronary endothelium is particularly susceptible to
these effects, leading to a Prinzmetal-type angina phenome-
non.5 Although 5-FU exerts acute effects on the coronary
arteries in terms of vasospasm and possibly thrombus forma-
tion, it has not been associated with the development of
accelerated coronary atherosclerosis.18
The addition of bevacizumab has a synergistic effect on the
vascular complications associated with 5-FU,5,84 which is
consistent with the hypothesis that cardiovascular effects are
mainly related to vasospasm and altered vascular reactivity.5
However, experimental studies have also implicated endothe-
lial andmyocardial cell apoptosis,5 although 5-FU causes a dose-
dependent increase in red blood cell viscosity and reduced blood
flow velocity that predispose to thrombus formation.
Preexisting coronary artery disease remains a risk factor for
5-FU-related vasospastic angina,18,85 which most likely reflects
the observation that vasospasm tends to occur at sites of
thrombus and plaque formation.18 Repeated ‘challenge’ with
5-FU or capecitabine tends to result in recurrent symptoms and
alternative agents should be used when toxicity has occurred.Anticancer Antibiotics
Anthracyclines
The anthracyclines, such as doxorubicin and epirubicin,
represent some of the most effective chemotherapy agents and
are used widely in the treatment of hematological and solidmalignancies including breast and gastric cancer, leukemia,
and lymphoma.4,86 They are also, however, associated with
profound cardiotoxicity and have a marked long-term effect
on cardiac structure and function. The principle side effect is a
cumulative, permanent, and dose-related cardiotoxicity with
consequent left ventricular dysfunction and heart failure.86,87
This is referred to as type 1 cardiotoxicity, and type 2
cardiotoxicity, which is generally associated with agents such
as trastuzumab, is not dose-related and usually resolves with
discontinuation of therapy.3 Anthracycline-associated
cardiotoxicity therefore appears to occur through direct
pathophysiological mechanisms rather than as a secondary
consequence of systemic hypertension, or arterial or venous
thrombosis.87,88
Bleomycin
Bleomycin exerts anticancer effects by damaging DNA and
disrupting the cytoskeleton. It causes a dose-dependent
reduction in endothelial cell growth and induction of
apoptosis. These vascular toxic effects at least in part explain
associated cardiovascular complications including myocardial
ischemia and infarction, thrombosis and thromboembolism,
pulmonary fibrosis, and Raynaud phenomenon.5
Microtubule targeted agents (including taxanes and
vinca alkaloids)
Microtubule targeted agents include the taxanes (eg,
paclitaxel), and the vinca alkaloids (eg, vincristine and
vinblastine).89 They act to alter the cellular microtubule mass,
which represents one of the most successful targets for
chemotherapy agents.89
The taxanes have significant antiangiogenic properties and
cause disruption of the cytoskeleton and impaired endothelial
cell function.5,90 At low doses, they block critical signalling
pathways and prevent cell motility and cell-cell
interactions.5,91 At higher doses, they cause microtubule
deficiency with endothelial cell detachment and apoptosis.5
Paclitaxel attenuates vascular smooth muscle cell migration
and halts endothelial cell proliferation.5,92 It might also have
prothrombotic effects through enhanced endothelial tissue
factor expression via selective activation of c-jun kinase.5,93
Docetaxel inhibits endothelial function in vitro and angio-
genesis in vivo5,94 and shows a dose-dependent vascular
toxicity, including a “fluid retention syndrome” due to
capillary leakage.5,95
The vascular side effects of taxanes are compounded when
used in combination with angiogenesis inhibitors. The
combination of bevacizumab with paclitaxel in patients with
advanced breast cancer increases the rate of severe thrombotic
events from 1.5% to 2.1%, and the combination of bev-
acizumab with a paclitaxel-carboplatin combination therapy
in patients with advanced non-small-cell lung cancer increases
the rate of severe hypertension from 0.7% to 7%.5,96,97
The vinca alkaloids, vincristine and vinblastine, are tubulin
binders that precipitate cell death and are primarily used in the
treatment of leukemia and lymphoma. Their main cardio-
vascular side effects are myocardial ischemia and infarction,
which tend to occur during or shortly after therapy and might
therefore be related to coronary artery vasospasm as a result of
cellular hypoxia.18
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Cardiovascular complications of cancer chemotherapy are
common and have increased in parallel with improved cancer
survival. This not only reflects the toxicity of classical and
novel agents, but also survival long enough after cancer
diagnosis for cardiovascular complications, or acceleration of
preexisting disease, to become clinically relevant.
The spectrum of vascular complications associated with
individual agents needs to be borne in mind when selecting
the optimum chemotherapeutic regimen on a patient by pa-
tient basis, taking into account background cardiovascular risk
and comorbidity. However, the ideal means to assess optimal
therapy and likelihood of ‘net benefit’ remains poorly defined.
In addition to conventional screening for cardiovascular risk
factors it remains to be seen whether noninvasive assessment
of endothelial function provides incremental value in risk
prediction. This question is particularly relevant because of
the central role of the endothelium in the pathophysiological
mechanisms underpinning vascular toxicity. A pragmatic
approach needs to be taken to balance the most efficacious
anticancer treatment with minimal vascular toxicity. Cross-
disciplinary management and decision-making for the group
of patients who require oncologic and cardiovascular expertise
has progressed but there remains room for improvement.
Reporting of vascular complications in clinical trials of
cancer therapies requires greater consistency. With the benefit
of clearer clinical end points we will be in a position to design
better prospective trials to evaluate potential vascular protec-
tive strategies for patients who undergo chemotherapy and
understand the best treatment of complications when they
have occurred. The appropriateness of continuing, reducing,
or changing chemotherapy agents and the best way to treat
cardiovascular and renal complications when they have
occurred is still an area of debate and often little consensus.
Patients have benefitted enormously from advances in
cancer and cardiovascular therapies. The challenge now exists
to keep pulling these 2 clinical and research disciplines closer
together so that investigators in these historically ‘separate’
areas can work collaboratively to ensure that a good oncologic
response to treatment does not come at an unacceptable
cardiovascular price.Funding Sources
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